02 May 2017
Tusk Therapeutics: UCL’s Cancer Immunology group publishes on the relevance of CD25 as a target in cancer
London and Stevenage, UK – 2 May 2017: Tusk Therapeutics, an immuno-oncology company, today announces that its collaborators, Dr. Sergio Quezada and Professor Karl Peggs of the Cancer Immunology group at University College London (UCL), published work in Immunity, a peer-reviewed medical journal, on targeting CD25 with an optimised antibody for the treatment of cancer.
The paper entitled, Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumor*, emphasises the relevance of CD25 as a target and discusses the promise of using an optimised antibody, targeting CD25, for the treatment of cancer in future combination approaches in immuno-oncology.
Tusk Therapeutics, Cancer Research Technology (Cancer Research UK’s commercial arm) and UCL announced in February 2017 that they have an exclusive licensing and collaboration deal aimed at progressing Dr. Quezada’s findings into the clinic.
“We are excited to be working with Cancer Research UK and Dr. Quezada and Prof. Karl Peggs. The recently published pre-clinical data shows great potential for therapeutic approaches targeting CD25 and Tusk is committed to translating these findings into the clinic. The recently published results demonstrate the relevance of CD25 as a therapeutic target and I believe that it shows a clear rationale for progressing it into a therapeutic setting.”
Luc DochezCEO of Tusk Therapeutics
The paper can be accessed here.
About Tusk Therapeutics Ltd
Tusk Therapeutics is a privately held immuno-oncology company focused on discovering and developing therapeutic antibodies that harness the power of the immune system to transform the treatment of cancer. The Company has established a diversified pipeline of antibodies against both novel and validated targets that have the potential to address a broad range of solid and haematological cancer indications. The Company’s two lead programmes are expected to enter preclinical development in 2017. The Company has strategic partnerships and licensing agreements with top research institutes including Cancer Research Technology, Cancer Research UK’s commercial arm and University College London. For further information about Tusk Therapeutics visit: www.tusktherapeutics.com
About UCL (University College London)
UCL was founded in 1826. We were the first English university established after Oxford and Cambridge, the first to open up university education to those previously excluded from it, and the first to provide systematic teaching of law, architecture and medicine. We are among the world's top universities, as reflected by performance in a range of international rankings and tables. UCL currently has over 38,000 students from 150 countries and over 12,000 staff. Our annual income is more than £1 billion.
Cancer Research Technology (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research. Further information about CRT can be found at www.cancertechnology.com and here http://www.cancertechnology.co.uk/how-we-are-advancing-discoveries-beat-cancer
About Cancer Research UK
Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook.